1. Home
  2. CASH vs URGN Comparison

CASH vs URGN Comparison

Compare CASH & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pathward Financial Inc.

CASH

Pathward Financial Inc.

HOLD

Current Price

$91.14

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$39.26

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CASH
URGN
Founded
1954
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
1996
2016

Fundamental Metrics

Financial Performance
Metric
CASH
URGN
Price
$91.14
$39.26
Analyst Decision
Buy
Strong Buy
Analyst Count
2
7
Target Price
$107.50
$29.29
AVG Volume (30 Days)
195.0K
717.0K
Earning Date
04-22-2026
05-06-2026
Dividend Yield
0.23%
N/A
EPS Growth
18.88
N/A
EPS
4.89
N/A
Revenue
$839,894,000.00
$1,128,000.00
Revenue This Year
$7.56
$129.09
Revenue Next Year
$6.02
$70.96
P/E Ratio
$18.56
N/A
Revenue Growth
11.29
N/A
52 Week Low
$65.93
$15.86
52 Week High
$101.26
$43.93

Technical Indicators

Market Signals
Indicator
CASH
URGN
Relative Strength Index (RSI) 57.99 N/A
Support Level $86.45 N/A
Resistance Level $94.61 N/A
Average True Range (ATR) 2.49 0.00
MACD 0.04 0.00
Stochastic Oscillator 82.42 0.00

Price Performance

Historical Comparison
CASH
URGN

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: